DIAKINE Trademark

Trademark Overview

On Wednesday, May 29, 2019, a trademark application was filed for DIAKINE with the United States Patent and Trademark Office. The USPTO has given the DIAKINE trademark a serial number of 88451067. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, September 23, 2025. This trademark is owned by Deka Biosciences, Inc.. The DIAKINE trademark is filed in the Education & Entertainment Services and Computer & Software Services & Scientific Services categories with the following description:

Providing a website featuring non-downloadable publications in the nature of testimonials, fact sheets, reports, articles, and videos in the pharmaceutical and biotechnology fields

Discovery, research, and development of pharmaceuticals and therapeutics for the treatment of cancer, immune related disorders, inflammatory bowel diseases, Crohn's, ulcerative colitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); research and development in the pharmaceutical and biotechnology fields; providing online information regarding medical and scientific research in the field of pharmaceuticals and therapeutics
diakine

General Information

Serial Number88451067
Word MarkDIAKINE
Filing DateWednesday, May 29, 2019
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, September 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 23, 2025

Trademark Statements

Goods and ServicesProviding a website featuring non-downloadable publications in the nature of testimonials, fact sheets, reports, articles, and videos in the pharmaceutical and biotechnology fields
Goods and ServicesDiscovery, research, and development of pharmaceuticals and therapeutics for the treatment of cancer, immune related disorders, inflammatory bowel diseases, Crohn's, ulcerative colitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); research and development in the pharmaceutical and biotechnology fields; providing online information regarding medical and scientific research in the field of pharmaceuticals and therapeutics

Classification Information

International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateThursday, June 20, 2019
Primary Code041
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 20, 2019
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDeka Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBethesda, MD 20816
Party NameDeka Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBethesda, MD 20816

Trademark Events

Event DateEvent Description
Saturday, June 1, 2019NEW APPLICATION ENTERED
Thursday, June 20, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 19, 2019LETTER OF SUSPENSION E-MAILED
Monday, August 19, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, August 19, 2019SUSPENSION LETTER WRITTEN
Thursday, March 5, 2020ASSIGNED TO LIE
Monday, February 1, 2021TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, February 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 19, 2019ASSIGNED TO EXAMINER
Monday, March 30, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, November 2, 2020ASSIGNED TO LIE
Tuesday, November 10, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, February 8, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 26, 2021SUSPENSION LETTER WRITTEN
Friday, May 13, 2022SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, November 11, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, May 18, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, February 26, 2021LETTER OF SUSPENSION E-MAILED
Friday, February 26, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, September 22, 2021SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, September 22, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, May 13, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, October 7, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, October 9, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, April 10, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, May 18, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, January 8, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, January 8, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, May 19, 2025NON-FINAL ACTION WRITTEN
Monday, May 19, 2025NON-FINAL ACTION E-MAILED
Monday, May 19, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 18, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 18, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 18, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 25, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 17, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 23, 2025PUBLISHED FOR OPPOSITION
Tuesday, September 23, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

diakine research development fields pharmaceuticals therapeutics providing nonalcoholic biotechnology pharmaceutical field